I. ramirez, “Benefits of a National Program for Adverse Drugs Reactions (ADRS) Surveillance in Diabetic Patients”, J. Drug Delivery Ther., vol. 12, no. 4-S, pp. 40–42, Aug. 2022, doi: 10.22270/jddt.v12i4-S.5618.